Neuronetics

FDA Approves TMS for Adolescent Depression: Study Shows Significant Symptom Improvement

- A recent study analyzed data from over 1,200 adolescents and young adults treated with Transcranial Magnetic Stimulation (TMS) for Major Depressive Disorder (MDD). - The study found that nearly 60% of patients experienced a significant reduction in symptoms, with over 36% achieving full remission, mirroring results in adult populations. - Based on these findings, the FDA approved TMS therapy for adolescents aged 15 and up, marking a significant advancement in treatment options. - TMS demonstrates promise as a safe, well-tolerated option for adolescents with MDD, especially those with treatment-resistant or partially-treated psychiatric illness.